Cuál es el precio por DelMar Pharmaceuticals, Inc. (DMPWW)

Precio por DelMar Pharmaceuticals, Inc. (DMPWW) es de$0.005

Cuál es la capitalización de mercado por DelMar Pharmaceuticals, Inc. (DMPWW)

Capitalización de mercado por DelMar Pharmaceuticals, Inc. (DMPWW) es $1.74K

DelMar Pharmaceuticals, Inc. (DMPWW) Ratio P/B

Kintara Therapeutics, Inc., previously known as DelMar Pharmaceuticals, Inc. until its rebranding in August 2020, operates as a clinical-stage pharmaceutical firm. Headquartered in San Diego, California, and established in 2009, the company is committed to advancing and bringing to market anti-cancer treatments for patients. Its development pipeline includes two advanced therapeutic candidates. One is VAL-083, a DNA-targeting agent poised for Phase III trials, designed to combat various drug-resistant solid tumors such as glioblastoma multiforme, ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The other is REM-001, a late-stage photodynamic therapy intended for conditions like cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and addressing access graft failure in hemodialysis patients. Kintara Therapeutics also maintains a strategic alliance with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for the manufacturing and commercialization of VAL-083 within the Chinese market.

Año	Ratio P/B	Cambiar
Not enough data for the provided dates.

Año

Ratio P/B

Cambiar

Not enough data for the provided dates.

Empresa	Ratio P/B	Diferencia del ratio P/B	País
Vertex Pharmaceuticals Incorporated VRTX.US	6.2613	-	US
Argenx SE ARGX.US	6.3483	-	NL
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	3.634	-	BE
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Empresa

Ratio P/B

Diferencia del ratio P/B

País